News - Novo Nordisk, IDegLira

Filter

Current filters:

Novo NordiskIDegLira

Popular Filters

Sanofi facing triple threat from Eli Lilly for diabetes treatment market space

Sanofi facing triple threat from Eli Lilly for diabetes treatment market space

26-06-2014

The imminent patent expiration of French pharma major Sanofi’s Lantus (insulin glargine) has opened…

BiosimilarsDiabetesdulaglutideEli LillyIDegLiraLantusLixiLanMarkets & MarketingNovo NordiskPharmaceuticalResearchSanofiToujeo

ADA 2014: New data on Novo Nordisk’s IDegLira and Victoza

ADA 2014: New data on Novo Nordisk’s IDegLira and Victoza

15-06-2014

A new Phase IIIa study shows that IDegLira, the once-daily single injection combination of Danish diabetes…

DiabetesIDegLiraNovo NordiskPharmaceuticalResearchVictoza

Novo Nordisk’s novel therapy could offer better outcomes for type 2 diabetes patients

Novo Nordisk’s novel therapy could offer better outcomes for type 2 diabetes patients

05-03-2014

Danish insulin giant Novo Nordisk has presented positive data at the Diabetes UK conference from its…

DenmarkDiabetesIDegLiraNovo NordiskPharmaceuticalResearchUK

Novo Nordisk’s IDegLira shows superior glycemic control and weight loss

Novo Nordisk’s IDegLira shows superior glycemic control and weight loss

03-12-2013

Danish insulin giant Novo Nordisk has presented positive new Phase III data from the investigational…

DiabetesIDegLiraNovo NordiskPharmaceuticalResearch

Novo Nordisk files Tresiba/Victoza combo IDegLira for EU approval

31-05-2013

Danish insulin giant Novo Nordisk (NOV: N) said today (May 31) that it has submitted a marketing authorization…

DiabetesEuropeIDegLiraNovo NordiskPharmaceuticalRegulationTresibaVictoza

News briefs on Sanofi, Novo Nordisk and GlaxoSmithKline/Amicus

20-12-2012

Two US subsidiaries of French drug major Sanofi (Euronext: SAN) have agreed to pay $109 million to resolve…

Amicus TherapeuticsAmigalDiabetesFIAspFinancialGlaxoSmithKlineHyalganIDegLiraLegalNorth AmericaNovo NordiskPharmaceuticalRare diseasesResearchSanofi

Back to top